Tag Archives: LVAD

Lower Mortality and Readmission Rates Reflect Medical, Mechanical Support and Transplant Innovations

Photo of care provider assisting a women seated in a wheelchair.One of the most compelling untold stories in medicine has been the dramatic reduction in mortality among heart failure patients over the past 30 years, and Penn State Health Milton S. Hershey Medical Center has been at the forefront of this effort.

Hershey Medical Center is certified by the United Network of Organ Sharing (UNOS) and has been offering heart transplant surgery since 1984. John Boehmer, MD, heart failure program director, says, ā€œIn the 1980s, heart failure was associated with an extraordinarily high mortality rate, and between the use of medical therapy, mechanical devices such as implantable defibrillators, pacemakers and left or right ventricular assist devices (LVADs, RVADs), as well as transplantation, that mortality has been reduced by nearly 80 percent. This improvement has come in incremental steps that have often gone unnoticed.ā€ Continue reading

Leave a comment

Filed under Patient Care

Technological Advances Lead to Improved Survival with Permanent Left Ventricular Assist Devices

HEART AND VASCULAR INSTITUTE CARDIOLOGISTS USE LATEST TOOLS TO EXPAND PATIENT OPTIONS

LVAD Case StudySince 1976, when surgeons at Penn State Hershey Medical Center implanted the first Pierce-Donachy left ventricular assist device (LVAD) in the country, the technology has helped thousands of patients with severe heart failure survive until a donor heart is available for transplant. Today, however, Penn State Hershey Heart and Vascular Institute uses LVAD therapy not only as a bridge-to-transplant (BTT), but also as long-term destination therapy (DT). In fact, half of the LVAD placements now performed at Penn State Hershey are for DT usage.

Although heart transplantation remains the gold standard for advanced heart failure, LVAD can provide a viable option for many. Patients must have three main qualifications to be considered for LVAD therapy: 1) must be in advanced heart failure, but contraindicated for a heart transplant, or too sick to wait for a transplant, 2) must have reached the limits of medical therapy, and 3) must have a life expectancy of more than two years. Continue reading

Leave a comment

Filed under Patient Care, Research, Treatments